



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>4</sup> :</b>  <b>C07J 5/00, A61K 9/72</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 86/ 03750</b>  <b>(43) International Publication Date:</b> 3 July 1986 (03.07.86)
<b>(21) International Application Number:</b> PCT/GB85/00588 <b>(22) International Filing Date:</b> 16 December 1985 (16.12.85)  <b>(31) Priority Application Number:</b> 8432063 <b>(32) Priority Date:</b> 19 December 1984 (19.12.84) <b>(33) Priority Country:</b> GB  <b>(71) Applicant (for all designated States except US):</b> RIKER LABORATORIES, INC. [US/US]; 19901 Nordhoff Street, Northridge, CA (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> JINKS, Philip, An- thony [GB/GB]; 37 Glebe Close, Mountsorrel, Lei- cestershire (GB).  <b>(74) Agent:</b> LLOYD WISE, TREGEAR & CO.; Norman House, 105-109 Surand, London WC2R OAE (GB).		<b>(81) Designated States:</b> AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), DK, FR (European patent), GB (Euro- pean patent), IT (European patent), JP, KR, LU (Eu- ropean patent), NL (European patent), NO, SE (Eu- ropean patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PHYSICALLY MODIFIED BECLOMETHASONE DIPROPIONATE SUITABLE FOR USE IN AERO- SOLS  <b>(57) Abstract</b>  A method for preparing a stable aerosol formulation of beclomethasone dipropionate in which the steroid is con- tacted with an alcohol containing 1 to 5 carbon atoms to form a crystalline solvate therewith, the crystalline material so formed being reduced to a particle size below 10 microns and thereafter dispersed in a composition comprising chloroflu- orocarbon propellents.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	GA Gabon	MR Mauritania
AU Australia	GB United Kingdom	MW Malawi
BB Barbados	HU Hungary	NL Netherlands
BE Belgium	IT Italy	NO Norway
BG Bulgaria	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland	ML Mali	
FR France		

-1-

PHYSICALLY MODIFIED BECLOMETHASONE  
DIPROPIONATE SUITABLE FOR USE IN AEROSOLS

5           This invention relates to beclomethasone dipropionate and in particular to the physical modification thereof to provide crystals suitable for incorporation into stable suspension aerosol formulations.

10           Anti-inflammatory steroids, e.g. beclomethasone dipropionate, have been micronised into particles of a size suitable for endopulmonary or nasal inhalation, i.e. particles in the size range 2 to 5 microns, which display crystal growth when incorporated into aerosol  
15           formulations containing halogenated hydrocarbons, e.g. trichloromonofluoromethane (Propellant 11), dichloro-tetrafluoroethane (Propellant 114) and dichloro-difluoromethane (Propellant 12). Crystals of a size  
20           larger than 20 microns are formed and such crystals are unsuitable for inhalation since their particle size is too great adequately to penetrate the trachea or nasal cavities. Investigations have revealed that the large crystals are not pure steroid but a solvate  
25           with one of the propellents, particularly Propellant 11.

          There are several known methods of inhibiting or reducing crystal growth of steroids in chlorofluoro-carbon propellents.

30           British Patent Specification No. 1 429 184 discloses the preparation of a stable aerosol formulation in which the steroid is contacted with a halogenated hydrocarbon to form a crystalline solvate therewith, the crystalline solvate so formed being

-2-

reduced to a particle size suitable for inhalation and thereafter being dispersed in an aerosol propellant.

United Kingdom Patent Application No. GB 2076422A discloses a process in which the increase of  
5 particle size is prevented at the suspending stage when the solubility of the steroid is reduced by using a low temperature (5 to -40°C) and by initially mixing only a small quantity of the propellant with the steroid.

10 German Offenlegungsschrift No. 3 018 550 discloses the formation of a solvate of beclomethasone dipropionate with ethyl acetate, reducing the crystals of a solvate to a particle size suitable for inhalation and thereafter contacting the micronised  
15 particles with chlorofluorocarbon propellents to form an aerosol formulation.

Canadian Patent Specification No. 1 147 652 discloses a method in which beclomethasone dipropionate is contacted with an alkane having from 5  
20 to 8 carbon atoms to form a solvate and the crystalline material is reduced to a particle size suitable for inhalation and thereafter contacted with chlorofluorocarbon propellents to form an aerosol formulation.

25 British Patent Specification No. 2 052 506A discloses a process for making a hemihydrate crystalline form of flunisolide by crystallizing flunisolide from an aqueous solution of an alkanol. The patent also discloses that when solvents such as  
30 ethyl acetate and methanol are used for crystallization of flunisolide clathrate, solvate or related solvent inclusion complexes are formed.

=3=

Journal of Pharmaceutical Sciences, Vol. 52, No. 8, August 1963, pages 781-791 discloses the formation of a pentanol solvent of fludrocortisone acetate. All the dissolution investigations were  
5 conducted in aqueous media and there is no reference to aerosol formulations.

We have now found that chlorofluorocarbon propellant stable forms of beclomethasone dipropionate can be achieved by forming crystalline solvates with  
10 lower alkanols.

Therefore according to the present invention there is provided a method for preparing a stable aerosol formulation of a beclomethasone dipropionate in which the steroid is contacted with an alcohol  
15 containing 1 to 5 carbon atoms to form a crystalline solvate therewith, the crystalline material so formed being reduced to a particle size below 10 microns and thereafter dispersed in a composition comprising chloro-fluorocarbon propellents.

20 The process of the invention provides stable suspension aerosol formulations of beclomethasone dipropionate, in a simple and effective manner. The process has significant procedural advantages over the more complex methods disclosed in British Patent  
25 Specification No. 1 429 184, United Kingdom Patent Application No. GB 2076422 and Canadian Patent Specification No. 1 147 652. The formulation of the invention exhibits a better thermal stability than compositions employing solvates with ethyl acetate as  
30 disclosed in German Offenlegungsschrift No. 3 018 550.

-4-

The alcohols used in the invention are monohydric alkanols or alkenols having from 1 to 5 carbon atoms. The preferred alcohol for use in the invention is isopropyl alcohol.

- 5       The general procedure for solvate preparation is to dissolve the steroid in the minimum quantity of anhydrous alcohol with heating, e.g. 70°C. The resulting solution is cooled and allowed to stand for a sufficient time for solvate crystals to separate  
10 out. Preferably, the solution is cooled to 0°C and maintained at this temperature for a period of about 24 hours. The solvate crystals may be filtered, dried and then micronised to the desired particle size, preferably in the range 2 to 5 microns.

- 15       The micronised particles may be incorporated into aerosol formulations by conventional techniques. The aerosol formulations containing the micronised solvates will generally simply comprise a suspension of the solvate in an appropriate propellant mixture  
20 together with a dispersing agent to stabilise the suspension. Suitable propellant mixtures generally comprise combinations or mixtures of Propellents 11, 12 and 114. Suitable dispersing agents include oleic acid, sorbitan trioleate and dioctyl sodium or calcium  
25 sulpho-succinate.

- In order to predict long term particle size stability of solvates in aerosol formulations, short term crystal growth determinations in Propellant 11 have been made. It has been found that the tendency  
30 towards crystal growth exhibited by a suspension of the micronised solvate in Propellant 11 alone is markedly more pronounced than that which is observed with formulations containing other chlorofluorocarbon

=5=

propellents. The reason for this effect is the significant polarity of Propellant 11 which is apt to promote drug dissolution (the first step towards recrystallisation and hence crystal growth); the most common constituent propellant of normal aerosol formulations is non-polar Propellant 12 and so dissolution occurs to a much lower degree.

It has been established that in the following Examples the level of crystal growth exhibited by a micronised solvate in Propellant 11 alone after three hours storage at room temperature is approximately equivalent to that which is found after six months storage at room temperature of an equivalent aerosol formulation of the micronised solvate in Propellents 11, 12 and 114, and which contains not more than 10% of Propellant 11.

The invention will now be illustrated by the following Examples.

20

25

30

-6-

Example 1Preparation of a batch of aerosol units using the solvation technique

- 5 a) Preparation of beclomethasone dipropionate solvate with isopropyl alcohol

Beclomethasone dipropionate (25 g) was dissolved under heat in isopropyl alcohol (200 ml). The solution was allowed to cool and then placed at 0°C for 24 hours. The resulting crystalline solid was filtered under vacuum and vacuum dried to remove residual solvent. The product was then ground to a powder in a pestle and mortar and micronised in a Trost fluid energy mill.

- b) Preparation of suspension aerosol units

20 4.441 g of the solvate from a) was dispersed in 300 g Propellant 11 containing 2.221 g sorbitan trioleate.

This suspension was added to 854 g Propellant 114 and 4839 g Propellant 12 contained in a pilot scale aerosol cold-filling vessel at -60°C. The suspension was filled into 375 aluminium vials using a fill weight of 16 g per vial. The units were sealed with valves delivering 50 mcl of suspension. After six months storage no significant change had occurred in the suspension quality.

25  
30



-7-

Example 2Beclomethasone dipropionate solvate preparation and  
particle size determination

5

a) Solvate Preparation

Beclomethasone dipropionate (10 g) was dissolved under heat (approximately 70°C) in the minimum quantity of alcohol. The solution was left at 0°C for 24 hours by which time solvate crystals had separated out. The solvate crystals were Buchner filtered, vacuum dried to remove residual solvent and micronised using a Trost fluid energy mill.

15

b) Suspension preparation

Solvate from the above process (200 mg) was suspended in Propellant 11 (50 g) containing oleic acid (0.1 mg/ml). The suspension was mixed for 5 minutes using a Silverson stirrer.

c) Suspension particle size stability

Suspension particle size was assessed using a laser diffraction technique. The particle size of the micronised, solvated raw material was firstly determined in aqueous suspension. Samples of the suspensions, as prepared in b), were then analysed after 3 hours storage at room temperature.

30

The following Table reports the alcohols used to prepare the solvates and the stability data.

=8=

Particle size stability of micronised beclomethasone dipropionate and derived solvates by the laser diffraction technique.

5	Sample		% < 2 $\mu$ % < 5 $\mu$ % < 10 $\mu$		
10	commercial beclomethasone dipropionate	1)	56.9	100	100
		2)	6.5	6.5	16
	ethanol solvate	1)	65.8	98.5	100
		2)	29.3	45.7	79.5
	isopropyl alcohol solvate	1)	45.7	93.7	100
		2)	42.3	88.2	100
	n-propanol	1)	53.1	86.5	100
		2)	41.7	72.3	97.5
	n-butanol	1)	42.3	79.6	93.9
		2)	20.6	36.7	66.3
15	isobutanol	1)	38.6	72.9	95.6
		2)	26.1	48.3	87.5
	n-pentanol	1)	62.4	100	100
		2)	34.7	63.7	96.6

- 1) Particle size of micronised raw material
- 2) Particle size after suspension in Propellent 11 for 3 hours at room temperature.

25      Figures 1 and 2 of the accompanying drawings represent profiles of the particle size stability of micronised commercial beclomethasone dipropionate and the micronised isopropyl alcohol solvate of beclomethasone dipropionate, respectively, after

30      suspension in Propellent 11.

=9=

Example 3Solvation of beclomethasone dipropionate using  
methanol or allyl alcohol (2-propen-1-ol)

5

The methanol and allyl alcohol solvates of beclomethasone dipropionate were prepared and micronised according to the method in Example 1. The results of crystal growth experiments are reported in the following Table.

10

Particle size stability of micronised beclomethasone  
dipropionate solvates by the laser diffraction  
technique.

15

Sample		% < 2 $\mu$	% < 5 $\mu$	% < 10 $\mu$
methanol solvate	1)	71.1	97.0	100.0
	2)	38.6	73.6	91.0
allyl alcohol solvate	1)	37.4	68.0	96.1
	2)	25.0	46.1	83.5

20

- 1) Particle size of micronised raw material.  
2) Particle size after suspension in Propellant 11 for 3 hours at room temperature.

25

It will be seen that there was a marked increase in particle size stability over unsolvated material (see Example 2) although the level of crystal growth was higher with both solvates than that found with the isopropyl alcohol solvate.

30

-10-

Example 4Stability of a beclomethasone dipropionate isopropyl  
alcohol solvate aerosol formulation

5

Batches of aerosols of the following  
formulation were prepared:

Beclomethasone dipropionate isopropyl	
alcohol solvate (micronised)	1.000
10 Span 85 (sorbitan trioleate)	0.500
Propellant 11	67.550
Propellant 114	192.293
Propellant 12	<u>1089.657</u>
	<u>1351.000</u>

15

Particle size by the laser diffraction techniqueTime : Initial

20

	<u>% &lt; 10.5 <math>\mu</math></u>	<u>% &lt; 5 <math>\mu</math></u>	<u>% &lt; 1.9 <math>\mu</math></u>
Unit 1	100	95.3	41.0
Unit 2	100	95.9	45.9

25 Time : 6 Months (room temperature storage)

	<u>% &lt; 10.5 <math>\mu</math></u>	<u>% &lt; 5 <math>\mu</math></u>	<u>% &lt; 1.9 <math>\mu</math></u>
Unit 1	99.9	96.0	47.3
Unit 2	100	92.6	41.8

30

-11-

Time : 6 Months (cycling temperature; consecutive 12  
hour periods at 15 and 37°C)

		<u>% &lt; 10.5 <math>\mu</math></u>	<u>% &lt; 5 <math>\mu</math></u>	<u>% &lt; 1.9 <math>\mu</math></u>
5	Unit 1	100	83.9	34.6
	Unit 2	100	85.7	33.0

The results indicate that the particle size of the formulation is virtually unchanged after storage for six months at room temperature. After 6 months storage under cycling temperature conditions, some crystal growth was found although this was lower than than found in samples of two commercially available suspension aerosol formulations of beclomethasone dipropionate, namely "Becotide" and "Clenil" when subjected to identical conditions.

=12=

## CLAIMS:

1. A method for preparing a stable aerosol formulation of beclomethasone dipropionate in which beclomethasone dipropionate is contacted with an alcohol containing 1 to 5 carbon atoms to form a crystalline solvate therewith, the crystalline material so formed being reduced to a particle size below 10 microns and thereafter dispersed in a composition comprising chlorofluorocarbon propellents.
2. A method as claimed in Claim 1, in which the alcohol is a monohydric alkanol or monohydric alkenol.
3. A method as claimed in Claim 2, in which the alcohol is isopropyl alcohol.
4. A method as claimed in any preceding claim, in which beclomethasone dipropionate is dissolved in alcohol under heating, the resulting solution is cooled and allowed to stand for a sufficient time for solvate crystals to separate out and thereafter the solvate crystals are separated, dried to remove residual solvent and reduced to the desired particle size.
5. A method as claimed in any preceding claim, in which the solvate crystals are reduced to a particle size in the range 2 to 5 microns.
6. An aerosol formulation comprising an aerosol propellant containing suspended therein, optionally in the presence of a dispersing agent, beclomethasone dipropionate in the form of a crystalline solvate with an alcohol containing 1 to 5 carbon atoms, the

=13=

particle size of substantially all of the steroid material being such as to permit inhalation into the human bronchial system when dispensed as an aerosol.

5 7. A formulation as claimed in Claim 6, in which the alcohol is monohydric alkanol or monohydric alkenol.

8. A formulation as claimed in Claim 7, in which  
10 the alcohol is isopropyl alcohol.

9. A formulation as claimed in any one of Claims 6 to 8, in which the solvate crystals are reduced to a  
15 particle size in the range 2 to 5 microns.

11. Beclomethasone dipropionate in the form of a crystalline solvate with an alcohol containing 1 to 5 carbon atoms, the particle size of substantially all  
20 of the steroid material being such as to permit inhalation into the human bronchial system when dispensed as an aerosol.

25

30

///

Fig.1.








Fig.2.





# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 85/00588

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>4</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 07 J 5/00; A 61 K 9/72																	
<b>II. FIELDS SEARCHED</b> <table border="1"> <tr> <th>Classification System</th> <th>Minimum Documentation Searched<sup>7</sup></th> <th>Classification Symbols</th> </tr> <tr> <td>IPC<sup>4</sup></td> <td></td> <td>C 07 J 5/00; A 61 K 9/00</td> </tr> </table>			Classification System	Minimum Documentation Searched <sup>7</sup>	Classification Symbols	IPC <sup>4</sup>		C 07 J 5/00; A 61 K 9/00									
Classification System	Minimum Documentation Searched <sup>7</sup>	Classification Symbols															
IPC <sup>4</sup>		C 07 J 5/00; A 61 K 9/00															
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup>																	
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table border="1"> <thead> <tr> <th>Category<sup>10</sup></th> <th>Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th>Relevant to Claim No. 13</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>EP, A, 0039369 (SCHERING CORP.) 11 November 1981 see claims (cited in the application) ---</td> <td>1-11</td> </tr> <tr> <td>A</td> <td>GB, A, 1429184 (ALLEN AND HANBURY LTD.) 24 March 1976 see claims (cited in the application) ---</td> <td>1-11</td> </tr> <tr> <td>A</td> <td>DE, A, 3018550 (CHIESI FARMACEUTICI) 11 December 1980 see claims (cited in the application) ---</td> <td>1-11</td> </tr> <tr> <td>A</td> <td>GB, A, 2107715 (GLAXO) 5 May 1983 see claims -----</td> <td>1-11</td> </tr> </tbody> </table>			Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. 13	A	EP, A, 0039369 (SCHERING CORP.) 11 November 1981 see claims (cited in the application) ---	1-11	A	GB, A, 1429184 (ALLEN AND HANBURY LTD.) 24 March 1976 see claims (cited in the application) ---	1-11	A	DE, A, 3018550 (CHIESI FARMACEUTICI) 11 December 1980 see claims (cited in the application) ---	1-11	A	GB, A, 2107715 (GLAXO) 5 May 1983 see claims -----	1-11
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. 13															
A	EP, A, 0039369 (SCHERING CORP.) 11 November 1981 see claims (cited in the application) ---	1-11															
A	GB, A, 1429184 (ALLEN AND HANBURY LTD.) 24 March 1976 see claims (cited in the application) ---	1-11															
A	DE, A, 3018550 (CHIESI FARMACEUTICI) 11 December 1980 see claims (cited in the application) ---	1-11															
A	GB, A, 2107715 (GLAXO) 5 May 1983 see claims -----	1-11															
<p><sup>10</sup> Special categories of cited documents: <sup>13</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>																	
<b>IV. CERTIFICATION</b> <table border="1"> <tr> <td>Date of the Actual Completion of the International Search</td> <td>Date of Mailing of this International Search Report</td> </tr> <tr> <td>25th March 1986</td> <td>16 APR. 1986</td> </tr> <tr> <td>International Searching Authority</td> <td>Signature of Authorized Officer</td> </tr> <tr> <td>EUROPEAN PATENT OFFICE</td> <td>M. VAN MOL </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	25th March 1986	16 APR. 1986	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	M. VAN MOL 							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
25th March 1986	16 APR. 1986																
International Searching Authority	Signature of Authorized Officer																
EUROPEAN PATENT OFFICE	M. VAN MOL 																

## ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/GB 85/00588 (SA 11712)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 09/04/86

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0039369	11/11/81	AT-B- E3774 AU-A- 5810780 AU-B- 533551	15/06/83 19/11/81 01/12/83
GB-A- 1429184	24/03/76	NL-A- 7305438 LU-A- 67462 FR-A,B 2182981 DE-A- 2320111 BE-A- 798458 AU-A- 5466073 CA-A- 994753 AU-B- 471577 US-A- 4044126 AT-A,B 352973 AT-B- 348115 JP-A- 49019014 US-A- 4364923 SE-B- 399642 US-A- 4414209	23/10/73 05/07/73 14/12/73 31/10/73 19/10/73 24/10/74 10/08/76 29/04/76 23/08/77 25/10/79 25/01/79 20/02/74 21/12/82 27/02/78 08/11/83
DE-A- 3018550	11/12/80	NL-A- 8003049	02/12/80
GB-A- 2107715	05/05/83	FR-A,B 2514769 BE-A- 894725 DE-A- 3238569 JP-A- 58090599 NL-A- 8204013 SE-A- 8205904 AU-A- 8946082 CA-A- 1189853 CH-B- 652134	22/04/83 18/04/83 05/05/83 30/05/83 16/05/83 18/10/82 03/05/84 02/07/85 31/10/85

For more details about this annex :  
see Official Journal of the European Patent Office, No. 12/82